Restricted accessCase reportFirst published online 2020-3
Successful treatment of refractory metastatic neuroblastoma with panobinostat in combination with chemotherapy agents and iodine-131-meta-iodobenzylguanidine therapy
In our case, who had refractory metastatic neuroblastoma, we use histone deacetylase inhibitor (panobinostat) in combination with chemotherapy agents and iodine-131-meta-iodobenzylguanidine (MIBG) therapy.
Management and outcome
This approach leads to successfully treat the patient. MIBG scan and bone marrow examination after therapy revealed no evidence of tumor. Now, she underwent autologous transplantation six months ago and free of tumor.
Conclusion
Panobinostat can cause apoptosis induction in refractory metastatic neuroblastoma in combination with MIBG therapy and chemotherapy.
LondonWBCastleberryRPMatthayKK, et al.Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol2005; 23: 6459–6465.
2.
GeorgakisMKDessyprisNBakaM, et al.Neuroblastoma among children in Southern and Eastern European cancer registries: variations in incidence and temporal trends compared to US. Int J Cancer2018; 142: 1977–1985.
3.
SharmaRMerJLionA, et al.Clinical presentation, evaluation, and management of neuroblastoma. Pediatr Rev2018; 39: 194–203.
4.
MurphyJMLimIIFarberBA, et al.Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass. J Pediatr Surg2016; 51: 285–288.
5.
LondonWBFrantzCNCampbellLA, et al.Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children’s Oncology Group study. J Clin Oncol2010; 28: 3808–3815.
6.
BagatellRLondonWBWagnerLM, et al.Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children’s Oncology Group study. J Clin Oncol2011; 29: 208–213.
7.
KushnerBHModakSKramerK, et al.Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. Cancer2013; 119: 665–671.
8.
KraalKCvan DalenECTytgatGA, et al.Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma. Cochr Datab Syst Rev2017; 4: Cd010349–Cd010349.
9.
DuBoisSGGroshenSParkJR, et al.Phase I study of vorinostat as a radiation sensitizer with 131I-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma. Clin Cancer Res2015; 21: 2715–2721.
10.
TranHCMarachelianAVenkatramaniR, et al.Oxaliplatin and doxorubicin for relapsed or refractory high-risk neuroblastoma. Pediatr Hematol Oncol2015; 32: 26–31.
11.
MosseYPLimMSVossSD, et al.Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol2013; 14: 472–480.
12.
HeathJACampbellMAThomasA, et al.Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma. Pediatr Blood Cancer2018; 65: e27055–e27055.
13.
WangGEdwardsHCaldwellJT, et al.Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One2013; 8: e76662–e76662.
14.
PintoNDuBoisSGMarachelianA, et al.Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: a new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer2018; 65: e27023–e27023.
15.
FedericoSMMcCarvilleMBShulkinBL, et al.A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma. Clin Cancer Res2017; 23: 6441–6449.
16.
RichardsonPGSchlossmanRLAlsinaM, et al.PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood2013; 122: 2331–2337.
17.
WoodPJStrongRMcArthurGA, et al.A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors. Cancer Chemother Pharmacol2018; 82: 493–503.
18.
WaldeckKCullinaneCArdleyK, et al.Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model. Int J Cancer2016; 139: 194–204.
19.
RichardsonPGLaubachJPLonialS, et al.Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther2015; 15: 737–748.
20.
TateCRRhodesLVSegarHC, et al.Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res2012; 14: R79–R79.
21.
HuangMWeissWA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med2013; 3: a014415–a014415.
